Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill....
Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity )
Also on site :
- Barbra Streisand Reveals Jaw-Dropping Details of Scandalous Proposal from Hollywood Icon!
- Today’s NYT ‘Strands’ Hints, Spangram and Answers for Tuesday, June 17
- NYT Connections Sports Edition Today: Hints and Answers for June 17